3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Second Sight Medical Products's 3-Year ROIIC % for the quarter that ended in Dec. 2021 was -982.86%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
EYESW's 3-Year ROIIC % is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 1.47
vs EYESW: -982.86
Second Sight Medical Products (NAS:EYESW) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Second Sight Medical Products 3-Year ROIIC % Related Terms
Second Sight Medical Products 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Second Sight Medical Products 3-Year ROIIC % Chart
EYESW vs SONX, LUCD, LHDX: 3-Year ROIIC % Comparison
For the Medical Devices subindustry, Second Sight Medical Products's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Second Sight Medical Products 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Second Sight Medical Products's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Second Sight Medical Products's 3-Year ROIIC % falls into.
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -8.933 (Dec. 2021) - -34.625 (Dec. 2018) )
/
( 1.305 (Dec. 2021) - 3.919 (Dec. 2018) )
=
25.692
/
-2.614
=
-982.86%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Second Sight Medical Products (EYESW) has a 3-Year ROIIC % of -982.86 as of Dec. 2021. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Second Sight Medical Products and its competitors.
Is Second Sight Medical Products' 3-Year ROIIC % too high?
Second Sight Medical Products' current 3-Year ROIIC % is -982.86.
How does Second Sight Medical Products' 3-Year ROIIC % compare to SONX and LUCD?
Second Sight Medical Products' 3-Year ROIIC % of -982.86 can be compared against companies in the Medical Devices & Instruments industry. The industry median 3-Year ROIIC % is 1.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.47, based on 797 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Second Sight Medical Products and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Second Sight Medical Products's current 3-Year ROIIC % is -982.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Second Sight Medical Products stock overvalued right now?
Second Sight Medical Products (EYESW) has a current 3-Year ROIIC % of -982.86. The current 3-Year ROIIC % is -982.86. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Second Sight Medical Products (EYESW), the current 3-Year ROIIC % is -982.86 as of Dec. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Second Sight Medical Products Business Description
Second Sight Medical Products Inc develops, manufactures, and markets implantable prosthetic devices to create an artificial form of useful vision for blind individuals. The company's product Argus II System treats outer retinal degenerations, such as Retinitis Pigmentosa, often referred to as RP. The company generates revenue from the sale of its Argus II retinal prosthesis systems, which include the implant and external components. Geographically, the company operates in the United States, Italy, China, and of which key revenue is derived from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EYESW has been successfully added to your 